ANPCY News and Press, Angle Plc Surrey ADR From 01/30/20

ANGLE plc ( OTCQX:ANPCY ): 1H GAAP EPS of -3.33p. More news on: ANGLE plc, ANGLE plc, Earnings news and commentary, Healthcare stocks news, , Read more ...

Full De Novo FDA Submission expected in Q1 CY20 Prospect of FDA clearance in Q3 CY20 GUILDFORD, SURREY / ACCESSWIRE / January 22, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that a successful face-to-face meeting with...

ANGLE plc ("the Company") Notification of Interim Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / January 8, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 31 October 2019 on Thur...

ANGLE plc ("ANGLE" or "the Company") Issue of Equity GUILDFORD, SURREY / ACCESSWIRE / December 23, 2019 / ANGLE plc (AIM:AGL and OTCQX:ANPCY), a world-leading liquid biopsy company, announces that it has received notice from an employee to exercise options over 16,667 ordinary s...

Leading Cancer Centre Demonstrates Use of Parsortix in Melanoma Parsortix harvests cancer cells from blood for analysis where cell surface markers systems are limited CTCs predicted relapse earlier than standard of care imaging GUILDFORD, SURREY / ACCESSWIRE / November 7, 2019 /...

ANGLE plc ("the Company") Results of 2019 Annual General Meeting GUILDFORD, SURREY / ACCESSWIRE / October 30, 2019 / ANGLE plc (OTCQX:ANPCY)(AIM:AGL), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions...

Positive Results Generated from Analytical Studies to Support Positive Pivotal Clinical Study for Potential FDA Clearance of Parsortix Liquid Biopsy System Potential FDA Clearance Expected in Q3 CY20 GUILDFORD, SURREY / ACCESSWIRE / October 30, 2019 / ANGLE plc (AIM:AGL)(OTCQX:...

Notice of AGM and Posting of Annual Report and Accounts GUILDFORD, SURREY / ACCESSWIRE / October 8, 2019 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that its AGM will be held at 2:00 pm on Wednesday 30 October 2019 at ANGLE plc, 10 Nugent Road, ...

EUROPEAN PATENT GRANTED TO QUEEN MARY UNIVERSITY LONDON FOR MEGAKARYOCYTE ANALYSIS TO ASSESS AGGRESSIVENESS OF PROSTATE CANCER ANGLE holds worldwide exclusive option over all megakaryocyte intellectual property Presence of megakaryocytes in prostate cancer linked to patient survival ...

PUBLICATION ON USE OF PARSORTIX IN HEAD AND NECK CANCER Opportunity for Parsortix to be used for PD-L1 analysis of CTCs to assess whether patients will benefit from immunotherapies GUILDFORD, SURREY / ACCESSWIRE / September 13, 2019 / ANGLE plc (AIM:AGL OTCQX:ANPC...